Literature DB >> 2223684

A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer.

I Jacobs1, D Oram, J Fairbanks, J Turner, C Frost, J G Grudzinskas.   

Abstract

Age, ultrasound score, menopausal status, a clinical impression score and serum CA 125 level were assessed to see how they could best distinguish between patients with benign (n = 101) and malignant (n = 42) pelvic masses. Each criteria used alone provided statistically significant discrimination. The most useful individual criteria were a serum CA 125 level of 30 U/ml (sensitivity 81%, specificity 75%) and an ultrasound score of 2 (sensitivity 71%, specificity 83%). Three criteria could be combined in a risk of malignancy index (RMI) which is simply calculated using the product of the serum CA 125 level (U/ml), the ultrasound scan result (expressed as a score of 0, 1 or 3) and the menopausal status (1 if premenopausal and 3 if postmenopausal). This index was statistically virtually as effective a discriminant between cancer and benign lesions as more formal methods. Using an RMI cut-off level of 200, the sensitivity was 85% and the specificity was 97%. Patients with an RMI score of greater than 200 had, on average, 42 times the background risk of cancer and those with a lower value 0.15 times the background risk.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2223684     DOI: 10.1111/j.1471-0528.1990.tb02448.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  152 in total

Review 1.  Management of gynaecological cancers.

Authors:  A Melville; A Eastwood; J Kleijnen; H Kitchener; P Martin-Hirsch; L Nelson
Journal:  Qual Health Care       Date:  1999-12

2.  Ascites and a raised serum Ca 125--confusing combination.

Authors:  L B Silberstein; A N Rosenthal; S W Coppack; K Noonan; I J Jacobs
Journal:  J R Soc Med       Date:  2001-11       Impact factor: 5.344

3.  Characterization of Adnexal Masses Using Contrast-Enhanced Subharmonic Imaging: A Pilot Study.

Authors:  Lauren J Delaney; Priscilla Machado; Mehnoosh Torkzaban; Andrej Lyshchik; Corinne E Wessner; Christine Kim; Norman Rosenblum; Scott Richard; Kirk Wallace; Flemming Forsberg
Journal:  J Ultrasound Med       Date:  2019-11-26       Impact factor: 2.153

4.  Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.

Authors:  Richard G Moore; Michael Craig Miller; Margaret M Steinhoff; Steven J Skates; Karen H Lu; Geralyn Lambert-Messerlian; Robert C Bast
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

5.  Targeting the use of ovarian cyst aspirate cytology.

Authors:  H Monaghan; A Al-Nafussi
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

6.  Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; Moune Jabre-Raughley; Amy K Brown; Katina M Robison; M Craig Miller; W Jeffery Allard; Robert J Kurman; Robert C Bast; Steven J Skates
Journal:  Am J Obstet Gynecol       Date:  2010-05-14       Impact factor: 8.661

7.  Ultrasound Features Improve Diagnostic Performance of Ovarian Cancer Predictors in Distinguishing Benign and Malignant Ovarian Tumors.

Authors:  Yong-Ning Chen; Fei Ma; Ya-di Zhang; Li Chen; Chan-Yuan Li; Shi-Peng Gong
Journal:  Curr Med Sci       Date:  2020-03-13

8.  Risk of malignancy index as an evaluation of preoperative pelvic mass.

Authors:  Zinatossadat Bouzari; Shahla Yazdani; Ziba Shirkhani Kelagar; Narges Abbaszadeh
Journal:  Caspian J Intern Med       Date:  2011

9.  The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass.

Authors:  Martina Montagnana; Giuseppe Lippi; Orazio Ruzzenente; Valentina Bresciani; Elisa Danese; Silvia Scevarolli; Gian Luca Salvagno; Silvia Giudici; Massimo Franchi; Gian Cesare Guidi
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

10.  A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.

Authors:  Richard G Moore; D Scott McMeekin; Amy K Brown; Paul DiSilvestro; M Craig Miller; W Jeffrey Allard; Walter Gajewski; Robert Kurman; Robert C Bast; Steven J Skates
Journal:  Gynecol Oncol       Date:  2008-10-12       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.